Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss

Journal of Viral Hepatitis

Volumn 21, Issue 12, 2014, Pages 909-916

  Zheng, Q ^a   Zhu, Y Y ^a   Chen, J ^a   Liu, Y R ^a   You, J ^a   Dong, J ^a   Zeng, D W ^a   Gao, L Y ^a   Chen, L H ^a   Jiang, J J ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

antiviral therapy; chronic hepatitis B; HBeAg loss; T cell reactivity; viral decline

Indexed keywords

ADEFOVIR DIPIVOXIL; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; ADENINE; ANTIVIRUS AGENT; HEPATITIS B ANTIGEN; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MALE; NATURAL KILLER CELL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER; PATHOLOGY; SECRETION (PROCESS); T LYMPHOCYTE; VIROLOGY; YOUNG ADULT;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER; MALE; ORGANOPHOSPHONATES; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VIRAL LOAD; YOUNG ADULT;

EID: 84911374800     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12261     Document Type: Article

References (20)

1. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
2. Gane EJ,. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008; 2 (3): 304-307.
3. Brunetto MR, Colombatto P, Bonino F,. Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. World J Gastroenterol 2009; 15 (5): 531-537.
4. Lau GK, Cooksley H, Ribeiro RM, et al,. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007; 12 (5): 705-718.
5. Boni C, Fisicaro P, Valdatta C, et al,. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81 (8): 4215-4225.
6. Webster GJ, Reignat S, Brown D, et al,. Longitudinal analysis of CD8 + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78 (11): 5707-5719.
7. Boni C, Penna A, Bertoletti A, et al,. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39 (4): 595-605.
8. Maini MK, Boni C, Lee CK, et al,. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191 (8): 1269-1280.
9. Tang TJ, Kwekkeboom J, Mancham S, et al,. Intrahepatic CD8 + T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol 2005; 43 (1): 45-52.
10. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM,. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 2011; 54 (2): 209-218.
11. Fisicaro P, Valdatta C, Boni C, et al,. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58 (7): 974-982.
12. Zheng Q, Zhu YY, Chen J, et al,. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2012; 20 (11): 801-806.
13. Xu D, Fu J, Jin L, et al,. Circulating and liver resident CD4 + CD25 + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177 (1): 739-747.
14. Hass HG, Bock T, Nehls O, Kaiser S,. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol 2009; 44 (8): 871-877.
15. Cooksley H, Chokshi S, Maayan Y, et al,. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4 + T-cell reactivity. Antimicrob Agents Chemother 2008; 52 (1): 312-320.
16. Chen Y, Li X, Ye B, et al,. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011; 91 (1): 23-31.
17. Tsai SL, Chen PJ, Lai MY, et al,. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89 (1): 87-96.
18. Wang FS, Zhang Z,. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009; 3 (5): 499-512.
19. Zou Y, Chen T, Han M, et al,. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 2010; 184 (1): 466-475.
20. Dunn C, Brunetto M, Reynolds G, et al,. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204 (3): 667-680.